MYC and ductal breast carcinoma in situ: Furthermore, in pure DCIS, heterogeneity of gene amplification was found in 3.7% (2/52) for HER2, 11.8% (2/17) for C-MYC, 22.7% (5/22) for CCND1 and 10% (1/10) for FGFR1 amplified cases (data not shown).